- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Patent holdings for IPC class C07D 213/74
Total number of patents in this class: 1541
10-year publication summary
|
110
|
140
|
100
|
90
|
83
|
78
|
98
|
78
|
68
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11297 |
32 |
| Bristol-myers Squibb Company | 4886 |
30 |
| Centre National de La Recherche Scientifique | 10052 |
30 |
| Boehringer Ingelheim International GmbH | 4762 |
25 |
| Institut Curie | 556 |
25 |
| F. Hoffmann-La Roche AG | 7942 |
20 |
| Universite de Montpellier | 960 |
20 |
| Abivax | 111 |
18 |
| Samsung Display Co., Ltd. | 32641 |
16 |
| Takeda Pharmaceutical Company Limited | 2945 |
16 |
| Celgene Quanticel Research, Inc. | 167 |
14 |
| Syngenta Participations AG | 3039 |
13 |
| Abbvie Inc. | 1781 |
13 |
| Oxular Acquisitions Limited | 21 |
13 |
| The Regents of the University of California | 19479 |
11 |
| Genentech, Inc. | 3864 |
11 |
| Janssen Pharmaceutica N.V. | 3625 |
11 |
| Nippon Soda Co., Ltd. | 884 |
11 |
| The Johns Hopkins University | 5519 |
10 |
| Vertex Pharmaceuticals Incorporated | 1570 |
10 |
| Other owners | 1192 |